Mechanistic data, response rates, survival outcomes, and resistance patterns were analyzed to provide an updated overview of therapeutic progress.<h4>Results</h4>Menin inhibitors have demonstrated significant activity in <i>NPM1</i>-mutated and <i>KMT2A</i>-rearranged AML, with agents such as revumenib and ziftomenib producing meaningful remission rates and ongoing studies exploring combination strategies to mitigate resistance. Here, NPM1 is linked to acute myeloid leukemia.